Diabetic nephropathy and antihypertensive treatment: What are the lessons from clinical trials?

American Journal of Hypertension

Volumn 16, Issue 8, 2003, Pages 689-697

  Lasaridis, Anastasios N ^a,b   Sarafidis, Panteleimon A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Albuminuria; Antihypertensive treatment; Clinical trials; Diabetic nephropathy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG PREFERENCE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 0042367765     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00864-1     Document Type: Review

References (63)

1. Murray CJ, Lopez AD: Evidence-based health policy lessons from the Global Burden of Disease Study. Science 1996;274:740-743.
2. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-1283.
3. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;141(Suppl):S1-S85.
4. Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000;13(Suppl):3S-10S.
5. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
6. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH: Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-1251.
7. Ruilope LM, Rodicio JL: Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993;2:962-967.
8. American Diabetes Association: Diabetic nephropathy. Diabetes Care 2000;23(Suppl 1):S69-S72.
9. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(Suppl 2):S46-S75.
10. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-2039.
11. Weir MR: Diabetes and hypertension: blood pressure control and consequences. Am J Hypertens 1999;12(Suppl):170S-178S.
12. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987;252:F1003-F1010.
13. Ritz E, Keller C, Bergis K, Strojek K: Pathogenesis and course of renal disease in IDDM/NIDDM: differences and similarities. Am J Hypertens 1997;10(Suppl):202S-207S.
14. Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28.
15. Waeber B, Feihl F, Ruilope LM: Diabetes and hypertension. Blood Press 2001;10:311-321.
16. Parving HH: Hypertension and diabetes: the scope of the problem. Blood Press 2001;10(Suppl 2):25-31.
17. US Renal Data System: USRDS 1999 annual data report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease 1999:25-38.
18. Bretzel RG: Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997;10(Suppl):208S-217S.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
20. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-138.
21. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10:39-45.
22. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-1080.
23. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994;45(Suppl): S150-S155.
24. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-1188.
25. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
26. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
27. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-720.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
29. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-183.
30. Kjeldsen SE, Os I, Farsang C, Mallion JM, Hansson L, Sleight P: Treatment of hypertension in patients with type-2 diabetes mellitus. J Hypertens 2000;18:1345-1346.
31. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999;353:617-622.
32. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.
33. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
34. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996;45:216-222.
35. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
36. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. J Am Med Assoc 1994;271:275-279.
37. EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792.
38. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomised, controlled trial. Ann Intern Med 1998;128:982-988.
39. Kon V, Fogo A, Ichikava I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-550.
40. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997;30:240-246.
41. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
42. Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F, Oddou-Stock P, Pecher E, Cheung R: The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-660.
43. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, Marion J: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-769.
44. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
45. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
46. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Shapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
47. US Renal Data System: USRDS 1995 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, April 1995.
48. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Masry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease study. Ann Intern Med 1995;123:754-762.
49. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-661.
50. Ruddy MC: Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens 2002;15:468-471.
51. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-1165.
52. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek DA, Douglas-Baltimore G, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, for the African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. J Am Med Assoc 2002;288:2421-2431.
53. Adler AI, Stratton IM, Neil AWN, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKDDS 36): prospective observational study. Br Med J 2000;321:412-419.
54. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461-1464.
55. Opie LH: Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Lancet 2001;358:1829-1831.
56. Kaplan NM: Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001;135:1079-1083.
57. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-1151.
58. Epstein M: Recent landmark clinical trials: how do they modify the therapeutic paradigm? Am J Hypertens 2002;15:825-845.
59. Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhaeger WH, deLeeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R, for the SystEur trial investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001;19:511-519.
60. Mogensen CE: The reno-protective role of AT(1)-receptor blockers. J Hum Hypertens 2002;16(Suppl 3):S52-S58.
61. Taal MW, Brenner BM: Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 2002;11:377-381.
62. Zanchetti A, Ruilope LM: Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002;20:2099-2110.
63. Chalmers J: "Treating hypertension" or "lowering blood pressure"? Extending the concept. Blood Press 2002;11:68-70.